observed what appeared to be a new condition in their children who had cystic fibrosis (CF) . Between July and September 1993 five patients presented. Four had a [2] [3] [4] week history of what appeared to be meconium ileus equivalent (MIE)/distal intestinal obstruction (DIOS) which did not respond to medical treatment. In these four patients ultrasound revealed dilatation and thickening of the ascending colon in all and stricture in some. Gastrografin enemas demonstrated strictures of the ascending colon and four required a hemicolectomy. The fifth patient had had a laparotomy at another hospital, also after failed medical treatment of distal intestinal obstruction. At second operation in Liverpool he was found to have serosal adhesions but no significant abnormality of the bowel wall. These five patients were reported in early 19941. All the children had been treated surgically and the appearance and histology of the resected colonic specimens of the first four children confirmed this was a new clinical entity unlike anything previously described in cystic fibrosis or other patients taking pancreatic enzymes. The condition is now known as fibrosing colonopathy.
WHAT IS FIBROSING COLONOPATHY?
Although fibrosing colonopathy may be suspected clinically, it is essentially a pathological diagnosis which requires a full thickness biopsy of the bowel wall-mucosal specimens obtained at colonoscopy are not adequate and may show very little abnormality. The features which are characteristic of fibrosing colonopathy are as follows: * Severe submucosal thickening by mature fibrous connective tissue * Intraluminal fusiform narrowing but with little change in the external bowel diameter, mainly in distal caecum and ascending colon * Loss of haustral pattern sometimes with a 'cobblestone' appearance of the intestinal epithelium, although the epithelium is generally intact but with some localized defects. Altered architecture suggests there has been repair of previous damage * Little or no evidence of inflammation or other lesions suggesting Crohn's disease. Some 
slight inflammation and fat around blood vessels
The appearance differs significantly from Crohn's disease, membranous colitis, distal intestinal obstruction, and from the lesions induced by potassium chloride or nonsteroidal anti-inflammatory drugs2 3. Fibrosing colonopathy has subsequently been reported from other clinics and countries. There are now 17 histologically proven cases of fibrosing colonopathy reported from the UK. There have been no further histologically proven cases in patients on high strength pancreatic enzymes reported from the UK since the subject was reviewed in 19964, but a further three children have developed the condition while taking a standard strength preparation, Nutrizym GR5,6. In the USA 29 patients were reviewed recently7, and further cases continue to be reported8-10. Some CF centres have had relatively more patients affected than others. For example, of 13 patients in the Philadelphia clinic with abdominal symptoms and taking high dose enzyme therapy, nine had operative resections of colonic strictures, which had the typical changes of fibrosing colonopathy and three have managed without surgery1l. In Indianapolis there were nine patients with fibrosing colonopathy and there was a clear association with very high doses of pancreatic enzymes12. A recent estimate put the USA number of affected children at 5213.
Only one adult CF patient with fibrosing colonopathy has been reported. She had severe lung disease and worsening symptoms of distal intestinal obstruction syndrome 4 months after starting Panzytrat 25 000. Her symptoms subsided after resection of 20 cm of the distal small bowel and the ascending colon. Histology of colon showed classical changes of fibrosing colonopathy that had not been predicted by the preoperative colonoscopy or computerized tomography scans14.
Only one of the seven cases reported from Copenhagen was confirmed histologically, others who were on large doses of enzymes (a mean dose of 45 000 lipase/kg/meal) had a colitic picture15. Similar cases with a colitic presentation have been reported161 7.
Fibrosing colonopathy has not been reported from France, Italy, Greece, Sweden, Norway, Australia or New Zealand. Paediatric Department, St James's University Hospital, Leeds, UK Radiological features are the subject of a number of reports. Four of five children had preoperative ultrasound and contrast enemas: all had wall thickening and stricture of the ascending colon18. One child had a recurrent stricture and required further resection after hemicolectomy. A report describes 15 children with abnormal barium enema results. The most common findings were stricture, loss of haustra and colonic shortening. Nine who had colonic resections had typical histological changes of fibrosing colonopathyl9,20. The radiological findings in ten children included mucosal irregularity, spiculation with nodular thickening of colonic wall and loss of haustration. Longitudinal shortening of the colon was a prominent feature. Histology was typical of fibrosing colonopathy20.
The pathology has been reviewed in 12 cases, eight colectomy specimens and four biopsies, with a review of the literature3. The affected colons had a cobblestone appearance, submucosal fibrosis, thickening of the muscularis propria and chronic inflammation. All the biopsies, which preceded colectomy in four cases, showed evidence of chronic inflammation and increased mucosal eosinophils.
Cases not proved by histology A number of reports mention patients who were likely to have fibrosing colonopathy but were not proved by histology, but these are relatively infrequent and probably do not represent the tip of a subclinical iceberg of fibrosing colonopathy. Three patients with radiological colonic strictures did not require surgical treatment2l; a 5 year old girl had increased colonic wall thickness on ultrasound (3.8 mm) and contrast evidence of shortening, colitis and loss of haustral pattern, but no discrete strictures22. There are other isolated case reports23-25.
A neonate who had not had pancreatic enzyme treatment An infant with cystic fibrosis presented with the clinical and histological features of fibrosing colonopathy in a full thickness rectal biopsy. The author suggests that meconium ileus, meconium ileus equivalent and fibrosing colonopathy may represent a continuum of one disease that is related to cystic fibrosis26. Certainly the incidence of meconium ileus is increased in children who subsequently develop fibrosing colonopathy, but the typical histological changes are not a recognized feature of neonatal meconium ileus.
BACKGROUND OF THE CONTROL OF MALABSORPTION IN CYSTIC FIBROSIS
Prior to the introduction of the standard acid-resistant enzyme preparations in the UK in the early 1 980s, intestinal malabsorption in CF was often inadequately controlled27.
Many patients had chronic distressing gastrointestinal symptoms despite treatment with large doses of the older unprotected enzyme preparations either as powders (Pancrex V, Viokase and Cotazym), when enclosed in gelatin capsules (Pancrex and Cotazym) or as pressed tablets (Pancrex V and Viokase). Unfortunately, 90% of the enzyme activity of these older preparations was destroyed by the gastric acid28.
The introduction of the acid-resistant microsphere preparations to the UK (Pancrease in 1983, Creon in 1985 and Nutrizym GR in 1988) had a major effect in improving the control of both the gastrointestinal symptoms and the malabsorption in the majority of patients29-31. These more effective enzymes permitted patients to take a liberal intake of fat that improved their energy intake. However, to achieve adequate control, many patients still required many enzyme capsules with each meal and snack32.
INTRODUCTION OF HIGH STRENGTH PANCREATIC ENZYMES
In 1992, CF patients welcomed the introduction of the high strength pancreatic enzymes (HSPEs) Pancrease HL and Nutrizym 22 (both microtablets) and Creon 25 000 (microspheres) which contained 3-5 times more lipase/ capsule than the standard preparations. Trials comparing high strength pancreatic enzymes and standard preparations on a lipase for lipase basis demonstrated good or better control of malabsorption and good patient acceptability with significantly fewer capsules required33-36. So popular were these new preparations that by late 1993 many CF clinics had changed the majority of their patients from a standard to a high strength pancreatic enzyme preparation.
Fewer capsules but relatively more lipase/kg/day was required. Although not apparent in the clinical trials of small numbers of patients, in practice we and others noticed that some patients did not achieve a direct conversion in equivalent doses of lipase/kg/day when changed from a standard to a high strength pancreatic enzyme prepara-tion1'32. The minimum guaranteed lipase content of the newer preparations was 3-5 times that of the standard preparations (e.g. Creon 8000 has 8000 and Creon 25 000 has 25 000 units of lipase/capsule; standard Pancrease has 5000 and Pancrease HL has 25 000 units of lipase/capsule). Yet some patients required up to two-thirds as many HSPE capsules to achieve satisfactory control. This resulted in a considerable increase in their total daily lipase intake, even though the total number of capsules they required was reduced. At the time, during 1993, this was regarded as only of financial importance as the cost of a unit of lipase was similar whether in a standard or high strength pancreatic enzyme preparation. At that time there was certainly no reason to suspect there would be any toxic effects from the increased doses of enzyme that followed 1 9 9 9 the change from a standard to a high strength preparation. The patients' parents and staff were very satisfied with the new enzyme preparations.
RECOMMENDATIONS OF THE COMMITTEE ON THE SAFETY OF MEDICINES
In 1993, Smyth et al. observed the first children with colonic strictures, which they described in their report early in 19941. In December 1993 the Committee on the Safety of Medicines (CSM) alerted UK CF clinicians to the occurrence of colonic strictures in the Liverpool patients and suggested that, unless there were special reasons, 'it would be prudent to advise patients with cystic fibrosis receiving high strength pancreatic enzyme preparations to change to other pancreatin preparations for the time being'. In November 1994, after 13 cases of fibrosing colonopathy had been identified in the UK, the CSM advised that 'unless special reasons exist, patients with cystic fibrosis should not use high-potency pancreatins'. In August 1995, following the report of two further CF children with fibrosing colonopathy who were taking a standard preparation Nutrizym GR5, the CSM recommended that the daily dose of any preparation should not exceed 10 000 units of lipase/ kg irrespective of the preparation. In November 1995 the CSM accepted the report of its May 1995 Working Party and recommended that:
'Pancrease HL, Nutrizym 22 and Panzytrat 25 000 will no longer be indicated for children aged 15 years and under with cystic fibrosis, and it would be prudent not to exceed a daily dose of enzyme equivalent to 10 000 units of lipase per kg per day, regardless of which preparation is used.'
In 1998 this remains the advice of the Committee on the Safety of Medicines.
STUDIES IN THE UK AND USA
In the UK an epidemiological study was performed and then a case-controlled study undertaken37. For the epidemiological study, all paediatricians and paediatric surgeons in the UK were asked to provide details of CF patients who had undergone surgery between 1984 and 1994. Surgical specimens were examined by the same two pathologists (three if there was disagreement). Fourteen cases of definite fibrosing colonopathy were identified of whom 12 were boys and six had received some or all of their CF care at the Liverpool CF paediatric clinic; 12 were aged between 2 and 7 years, the other two were 10 and 13 years old.
In January 1994, the US CF Foundation (CFF) requested 114 CF centres to report any occurrence of colonic were received, and 15 eventually met their case definition for fibrosing colonopathy (more cases were reported subsequently)7. The children were younger than CF controls (mean 4.2 versus 14.8 years). Five of the 15 (33%) had previously had meconium ileus. However, only eight were using a pancreatic preparation containing more than 20000 IU lipase/capsule. The CFF considered that conclusions as to the relationship with high strength pancreatic enzyme preparations could not be made, but indicated that more detailed information would be available on use of enzymes, characteristics of the patients, use of other medications and the 'manufacturing specifics of the formulations involved'. The doses of enzymes taken by patients in the US study ranged from 6700 to 29 100 units of lipase/kg/meal and all had taken 'delayed release products'. The brands or formulations were not reported7.
On the basis of these findings the FDA advised that all products containing >20000 units of lipase/capsule be withdrawn from the market. It had been previously noted that doses greater than 6000 units of lipase/kg/meal had been associated with colonic strictures and it was suggested that more than 2500 units of lipase/kg/meal should be used with caution38.
The UK case-controlled study
In the UK controlled study each fibrosing colonopathy patient was compared with four CF controls matched for age and obtained from the UK CF Survey a comprehensive register of all UK CF patients37. This study confirmed the suspected association between fibrosing colonopathy and the use of high strength pancreatic enzyme preparations; there was no association with the use of the standard Creon or Pancrease preparations. Also, there was a clear and significant brand difference between the high strength pancreatic enzyme preparations as only Pancrease HL and Nutrizym 22, but not Creon 25 000, were associated with fibrosing colonopathy. This association was dose-related37.
Pancrease HL and Nutrizym 22 are essentially the same microtablet preparation with a covering containing methacrylic acid copolymer (Eudragit L30 D55), whereas Creon 25 000 is a microsphere preparation and contains no copolymer39.
The CF Foundation case-controlled study In 1997 the US CF Foundation reported a controlled case study to investigate the relationship between the dose and type of pancreatic supplement and fibrosing colonopathy8.
Twenty-nine CF patients (mean age 5 years) with histologically proven fibrosing colonopathy were compared with 105 control patients (mean age 5.2 years) matched for age, strictures over the previous 3 years. Forty-five reports 43 time of surgery and medical centre. The mean enzyme dose of the fibrosing colonopathy cases was 50 046 units of lipase/kg/day and of the controls 18 985 units of lipase/ kg/day. Also, the affected patients had more symptoms and used more H2 blockers and rhDNase (Pulmozyme). Thus, there was a strong correlation between fibrosing colonopathy and a high enzyme dose but not with the strength of the individual capsules; the coating or the manufacturer of the products were not reported to be associated with the development of fibrosing colonopathy. The study was not designed to detect a brand difference as the control patients for individual fibrosing colonopathy patients were selected from the same CF centre and were receiving the same brand of enzyme. Therefore, the US study was a dose-response study for the microtablets that were used by all the cases and most of the controls. However, in view of the definite dose association with enzyme dose, it was recommended that the daily dose of enzymes should remain below 10000 units of lipase/kg/day for most CF patients8.
Since then in the USA, 10 further patients in 1995 and three in 1996 have required surgery for fibrosing colonopathy; they resembled the main series. Also during this 2-year period, a further 12 unoperated and two operated patients were identified where fibrosing colonopathy was suspected but not confirmedl0.
The UK case-controlled study generated two hypotheses as to the cause of fibrosing colonopathy. The first hypothesis was that fibrosing colonopathy was related to the inappropriately high doses of the active enzymes reaching the distal bowel, which had an adverse effect on the colon. The second was that some other constituent of the enzyme preparations was toxic to the colon, e.g. the coating of the enzymes. The two microtablet preparations associated with fibrosing colonopathy in the UK both had a protective coating containing methacrylic acid copolymer (Eudragit L30 D55). This copolymer contains methacrylic acid and ethyl acrylate, both of which are known have a toxic effect on the guts of animals. It was suggested that the methacrylic acid copolymer present in the coating of some preparations might be an important factor in causing fibrosing colonopathy2. Following the advice on enzyme use from the CSM, there have been no further UK cases of fibrosing colonopathy in CF patients taking high strength pancreatic enzyme preparations since July 1994. However, two further children with fibrosing colonopathy came to surgery in May and June 1995; both were taking standard Nutrizym GR, a preparation which has contained copolymer since 19935. Nutrizym GR is still available for use in children in the UK, and in 1997 another 15 month old CF child developed fibrosing colonopathy whilst taking Nutrizym GR6. Since 1994, total enzyme doses have been reduced in most CF patients without any adverse effects on absorption, nutrition or growth40'41.
STUDIES TO DETERMINE THE AETIOLOGY OF FIBROSING COLONOPATHY
Following the suggestion that the covering of the microtablet preparations (Pancrease HL and Nutrizym 22) may be important, Van Velzen carried out a number of experimental animal studies42. Methacrylic acid copolymer (Eudragit L30 D55) is present in the covering of the microtablet preparations Pancrease HL, Nutrizym 10 and 22, Ultrase MT 6/12/20/24/30 (Eurand), Panzytrat 25000, Pancrease MT 4/10/16/25/32 (Nordmark), and in the Nutrizym GR granules (Eurand) since 1993. There is no copolymer in the standard strength microsphere preparations Pancrease (McNeil), Creon 8000, Creon 10000 or Creon 25 000 (Solvay).
Methacrylic acid copolymer consists of equal quantities of the monomers methacrylic acid and ethyl acrylate. Gavage studies in the rat with one of these two monomers (ethyl acrylate) have shown that it causes superficial gastric mucosal ulcerations, submucosal oedema and fibrosis, but the colons were not examined43. In Van Velzen's studies in adolescent pigs, gavage studies of 10, 50 or 500 mg/kg/day of Eudragit L30 D55 for 7 days caused submucosal fibrosis, but not full fibrosing colonopathy, at all dose levels in seven of nine animals. These doses were comparable to those received by CF patients taking the high strength pancreatic enzymes which contain methacrylic acid copolymer. The monomer components of Eudragit L30 D55 (methacrylic acid and ethyl acrylate 50/50 mixture) at dose levels of 0.015-50mg/kg/day, representing possible residues that may be present in Eudragit L30 D55, did not produce comparable changes. Sodium lauryl sulphate (SLS) and polysorbate 80 are surfactants which may enhance the effect of methacrylic acid copolymer (surfactants plus copolymer= Eudragit L30 D55) and high doses of them also cause oedema of the lower small bowel and caecum but not typical fibrosing colonopathy. Thus, only the combination of copolymer plus the surfactants caused typical fibrosing colonopathy in pigs4. It has been suggested that the mucosal defects, recently demonstrated in fibrosing colonopathy specimens and possibly caused by the surfactants, could facilitate mucosal transport of the polymer component45.
Children with fibrosing colonopathy have been estimated to consume anywhere between 30 and 255 mg/kg/day of methacrylic acid copolymer (Eudragit L30 D55). High strength pancreatic enzyme capsules contain 30-70mg of methacrylic acid copolymer (Eudragit L30 D55). In the UK study the controls were taking 60-70 mg/kg/day and patients who developed fibrosing colonopathy 100-250mg/kg/day. The manufacturer had suggested an upper safe limit of 2 mg/kg/day for adults. A small amount may be absorbed and the increased mucosal permeability described in CF patients46 and the mucosal lesions in Supplement No. 37 Vo u me 92 1 9 9 9 fibrosing colonopathy cases45 may both be relevant to the pathogenesis of colonic strictures.
Submucosal changes typical of fibrosing colonopathy do not appear unless there is exposure to methacrylic acid copolymer. Postmortem samples from 14 CF patients (without strictures) were examined for mucosal ulceration, submucosal fibrosis and vascular and neuronal complex changes. None of the patients had been exposed to methacrylic acid copolymer and nine died before and five after the introduction of this compound. Neither group showed ulceration or fibrosis, whereas vascular changes and neuronal complex increase (both described in fibrosing colonopathy) were found in four of five and six of nine patients respectively47. The authors concluded that in the absence of methacrylic acid copolymer there were no submucosal changes typical of fibrosing colonopathy, irrespective of duration of exposure. Also, vascular and neuronal complex changes, often discussed in relation to fibrosing colonopathy, reflect changes which are common to all CF patients rather than having relevance to fibrosing colonopathy. Table I lists the enteric coated pancreatic enzymes that are available in the UK and the USA. A recent study further investigated the possibility that the enzyme coating accounted for the brand differences apparent in the UK study39. A detailed analysis of the relationship between patterns of enzyme use and 16 confirmed and 14 suspected cases of fibrosing colonopathy was made after obtaining further details of the UK and US patients. Fibrosing colonopathy was only found in CF children who had received those brands of pancreatic enzymes that had a coating of methacrylic acid copolymer for a period of at least 6 months. In no instance had only a standard microsphere preparation been used. Also, this study confirmed the dose relationship with those preparations which contained the copolymer39.
A possible factor in the causation of fibrosing colonopathy may be more distal release of enzyme activity with the high strength pancreatic enzyme preparations, delivering an inappropriately high dose of enzymes to the colon. A breath test study using stable isotopes in the form of a mixed triglyceride (1,3-disteraryl-2-carboxyl octanoyl glycerol) labelled with 1 3C was used to measure the degree and site of maximum lipolysis and compared standard Creon 8000, Creon 25 000 and Pancrease HL. There was no difference in the timing or degree of lipolysis when the standard (Creon 8000), copolymer containing high strength enzyme preparation (Pancrease HL) and the high strength preparation without copolymer (Creon 25 000) were used in equivalent lipase doses48. However, there are studies which do show an abnormally high level of pancreatic enzymatic activity in the distal small bowel49 and, as noted, the absolute doses of enzyme did increase considerably in many CF patients on changing from a standard to a high strength preparation. Thus, delayed release cannot be discounted as having a contributory effect in the causation of fibrosing colonopathy.
ULTRASOUND STUDIES TO DETECT SUBCLINICAL FIBROSING COLONOPATHY
An ultrasound study from the Brompton Hospital reported an increased colonic thickness in patients previously treated with high strength pancreatic enzymes, and suggested that the protease was a factor, however, there was some confusion over the protease content of the various preparations50. In a further analysis of their figures there was still a significant dose relationship between the daily high strength pancreatic enzyme consumption and the colonic thickness51. High strength preparations other than Creon 25 000 were disproportionately represented amongst patients with the most marked colonic thickening. The authors referred to the possibility of a:
'Sub-clinical spectrum of colonic abnormality, detectable by ultrasound scan, some of which would appear to be reversible and directly related to enzyme dose and so may be a forerunner of fibrosing colonopathy and stricture formation.'
The suggestion that there may be a subclinical spectrum of abnormality related to prior use of the high strength pancreatic enzyme preparations prompted us to study the Leeds CF children who had been taking a variety of high strength pancreatic enzymes, mostly Pancrease HL or Creon 25 00052. The colonic thickness of the CF children measured by ultrasound varied between 0.7 and 2.5 mm (mean 1.2 mm) and that of controls between 0.6 and 1.4mm (mean 1.0mm). There was no significant relationship between the dose, type or make of enzymes and colonic thickness, i.e. we could not demonstrate a 'subclinical spectrum of colonic abnormality'S0. However, there was a trend towards increased colonic thickness in children who had received preparations containing --------copolymer, although this was not statistically significant. In our adult CF clinic no significant relationship was found between the enzyme dose or the consumption of copolymer adjusted for the patients' weight53.
An ultrasound study from Southampton of CF patients who were taking substantial doses of Creon 25 000 failed to show a relationship between enzyme dose and colonic thickness, but the latter did increase with age. The authors' conclusion that colonic thickness was related to age and not to the high strength enzyme preparation used is, of course, only valid for Creon 25 000. Their findings are, nonetheless, reassuring as far as this preparation is concerned54.
In an ultrasound study of 201 German CF patients, 193 were taking a variety of enzymes-Creon, Creon 25 000 (neither containing copolymer) and Panzytrat 10 000, 20000 and 40000 (all containing copolymer). There was a clear relationship between colonic wall thickness and the use of high strength enzyme preparations (defined as those containing more than 20 000 IU lipase/capsule). A number of patients on the high strength preparations had a colonic wall thickness of over 4mm and could have already been developing early fibrosing colonopathy. It was difficult to analyse the difference between the high strength enzyme preparations which contained copolymer (Panzytrat) from those that did not (Creon), although patients taking Panzytrat 40000 (the preparation with the highest lipase content and also containing copolymer) did more frequently have both ileal and caecal wall thickening55.
One further German ultrasound study relating colonic thickness and enzyme use showed no association with either enzyme dose or the preparation used, but the data used to arrive at this conclusion was not supplied. The patients were taking both Creon 10 and Creon 25000 (both without copolymer) and Panzytrat 10 000, 20 000, 25 000 and 40 000 (all containing copolymer). The authors concluded that there was 'a genuine intestinal involvement in cystic fibrosis; in a few cases this could lead to fibrosing colonopathy'. As five patients had a colonic thickness of more than 5 mm, in one case it was 6.5 mm, there was a real possibility that the patients did indeed already have early fibrosing colonopathy56.
Abdominal computed tomography was abnormal in 10 of 26 CF patients. Abnormalities included colonic wall thickening (mean 6.4mm), mesenteric infiltration, increased pericolonic fat and mural striation. Colonic wall thickness in the patients regarded as normal was less than 2 mm. No strictures were identified but four of the abnormal patients were considered to have inflammatory changes57.
THE INFLUENCE OF RECENT EVENTS ON THE MANAGEMENT OF MALABSORPTION IN CYSTIC FIBROSIS
There is now more careful monitoring of the intestinal malabsorption in many, but unfortunately not all, CF clinics, where previously the dose of enzymes had been largely determined by the parent or patient on the presence or absence of symptoms58. Hopefully, the mistaken belief that recurrent abdominal pain always means more enzymes are needed, which was the basis of so many of the fibrosing colonopathy histories, is now less common. Now troublesome pain means investigations are indicated to determine the cause, rather than responding by an automatic increase in the dose of pancreatic enzymes. The investigations will usually include an X-ray of the abdomen, an ultrasound scan and even a contrast enema. Demonstration of persisting malabsorption by even semi-quantitative methods59 provides valuable information and has become more common, but is unfortunately not routine in all clinics. Finally, some demonstration of pancreatic abnormality can now be easily achieved using faecal pancreatic elastase 160. A normal faecal elastase 1 in a CF patient taking pancreatic enzymes suggests the enzymes are not needed and should also lead to a re-evaluation of the diagnosis61.
Many CF children take standard Creon 10 000, and a few parents have preferred their child to continue with Creon 25 000. I believe that Creon 25 000 carries no risk of fibrosing colonopathy. The evidence is so strong that pancreatic enzyme preparations containing methacrylic acid copolymer (Eudragit L30 D55) are an important contributory factor in causing fibrosing colonopathy that I believe that Pancrease HL, Nutrizym 20 and 10, Nutryzim GR, or any other enzyme containing copolymer, should be avoided by all patients with CF. Panzytrat 25 000 is no longer available in the UK.
Effective pancreatic enzyme therapy should abolish gastrointestinal symptoms and signs particularly pain, abdominal distension and palpable masses. Bowel habit should be normal and the stools should be of normal appearance. Fat absorption should be over 85% and is frequently over 90% of intake. Nutrition and growth should be normal. In most CF patients these goals can be achieved with doses less than or only slightly in excess of 10 000 units of lipase/kg/day and rarely is more than 15 000 units/kg/ day required40. Median doses of pancreatic enzymes required for acceptable control of malabsorption (as judged by faecal fat measurements) and maintenance of normal growth, in Leeds CF children in the age groups 0-5 years, 5-10 years, 10-15 years and over 15 years, were 9036, 9393, 7853 and 5047 IU respectively of lipase/kg/day.
THE PATIENTS WHO HAD FIBROSING COLONOPATHY
The majority of the 17 UK children who had fibrosing colonopathy have improved following varying degrees of colectomy. At operation, they were aged 0.9-13.3 years Su ppl ement No 3 7 Volume 92 1 9 9 9 (mean 5. 1, median 4.9 years), 13/17 (77%) were male, and 5/17 had neonatal surgery for meconium ileus. A minority who had most of the colon removed continue with significant bowel problems of frequent loose stools, incontinence and malabsorption. One patient died at 11 years from respiratory complications unrelated to the fibrosing colonopathy. The progress of the 17 UK cases up to 1996 is described in more detail elsewhere4. There is no further progress as to which other aetiological factors contributed to the development of fibrosing colonopathy in these patients.
CONCLUSIONS
The aims and practical details of management of the malabsorption in CF patients has been reviewed in detail elsewhere62'40. The need for regular careful gastrointestinal monitoring has been stressed, as has the need to check absorption periodically, even if only by one of the very useful semi-quantitative methods, e.g. stool microscopy59. It is particularly important to investigate CF patients having chronic abdominal symptoms rather than merely increasing their dose of enzymes.
Fibrosing colonopathy is undoubtedly a new condition and was unknown in the UK before high strength pancreatic enzymes became available. The condition appears to develop only in a minority of CF patients within [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] months of starting an enzyme preparation that contains methacrylic acid copolymer (Eudragit L30 D55). Although the first case that occurred in the USA in 1991 was taking a low strength preparation, it was apparently a copolymer coated preparation39. In the UK there has only been one additional case of fibrosing colonopathy, in 1997, since the two children taking Nutrizym GR were reported in 19955. This most recent child had also been taking Nutrizym GR, the only standard strength preparation that contains the copolymer Eudragit L30 D55. No CF patient on copolymer-free preparations (i.e. standard Pancrease, standard Creon or Creon 25 000) had developed fibrosing colonopathy63.
All the published evidence suggests that fibrosing colonopathy is in some way related to the use of large doses of the pancreatic enzymes which contain methacrylic acid copolymer (Eudragit L30 D55). It is very probable that there are other factors that determine which patients exposed to these products will develop fibrosing colonopathy. Subclinical gut mucosal inflammation64 and even an immunological component have been suggested as other possibilities65. However, with the information available at present, it would seem sensible for those prescribing pancreatic enzymes for children to avoid those which contain copolymer and use only Creon 10000, standard Pancrease or Creon 25 000. It is desirable to prescribe enzymes in doses which are just adequate to control both symptoms and malabsorption63. Fortunately, the outbreak of fibrosing colonopathy seems to have abated following the advice to reduce enzyme doses irrespective of the preparation used. In those patients still using a copolymer-containing preparation (as are many in the USA), this has had the effect of reducing the intake not only of lipase (and other enzymes) but also the intake of the copolymer whose effects are known to be dose-dependent. It is unknown whether the consumption of lower doses of copolymer over more prolonged periods is completely free of side-effects a further reason for avoiding such preparations. The advise from the CSM remains unchanged since 1995.
Finally, it is important that the occurrence of this rare but very serious complication results in more accurate monitoring of the gastrointestinal tract in CF patients. The totally unexpected appearance of fibrosing colonopathy reminds paediatricians yet again that an apparently benign treatment may turn out to have totally unexpected and quite disastrous side-effects.
